INBRIJA

Peak

levodopa

NDAINHALATIONPOWDER
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.

Pharmacologic Class:

Aromatic Amino Acid

Clinical Trials (5)

NCT07227896N/ANot Yet Recruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

Started Mar 2026
100 enrolled
Parkinson's Disease
NCT07382440N/ANot Yet Recruiting

A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium

Started Jan 2026
120 enrolled
Parkinson's Disease
NCT07284342N/ARecruiting

A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa

Started Nov 2025
103 enrolled
Advanced Parkinson's Disease
NCT06965374N/ARecruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease

Started Jun 2025
270 enrolled
Parkinson Disease
NCT06916507N/ARecruiting

Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)

Started May 2025
125 enrolled
Parkinson's Disease

Loss of Exclusivity

LOE Date
Oct 21, 2033
92 months away
Patent Expiry
Oct 21, 2033

Patent Records (5)

Patent #ExpiryTypeUse Code
RE43711
Feb 3, 2029
U-2484
8545878
Nov 16, 2032
Product
8685442
Nov 16, 2032
Product
8945612
Nov 16, 2032
Product
9393210
Nov 16, 2032
Product